Elevance Health, Inc. $ELV Stock Position Lifted by New York State Common Retirement Fund

New York State Common Retirement Fund raised its stake in Elevance Health, Inc. (NYSE:ELV) by 4.6% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 321,791 shares of the company’s stock after purchasing an additional 14,219 shares during the quarter. New York State Common Retirement Fund’s holdings in Elevance Health were worth $103,977,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ELV. Norges Bank acquired a new position in shares of Elevance Health in the second quarter worth $1,148,379,000. Sanders Capital LLC increased its position in Elevance Health by 24.7% in the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares during the last quarter. Beutel Goodman & Co Ltd. purchased a new stake in shares of Elevance Health during the 2nd quarter worth about $293,141,000. Vanguard Group Inc. lifted its holdings in shares of Elevance Health by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock valued at $8,890,419,000 after buying an additional 704,790 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Elevance Health by 30.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,076,668 shares of the company’s stock valued at $807,741,000 after buying an additional 487,579 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Up 1.3%

Elevance Health stock opened at $346.33 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm has a fifty day moving average price of $351.21 and a two-hundred day moving average price of $328.99. The firm has a market cap of $76.97 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 1.86 and a beta of 0.51.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period last year, the business posted $3.84 earnings per share. The firm’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio is presently 27.96%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat estimates: ELV reported $3.33 EPS vs. $3.10 consensus and revenue growth year-over-year, helped by higher premiums and strong Carelon revenues—an outcome investors often reward. Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums
• Positive Sentiment: Dividend bump: the company raised its quarterly dividend to $1.72 (annualized yield ~2.0%), a small cash-return signal that can support the share price.
• Positive Sentiment: Brokerage sentiment remains constructive: ELV retains an average “Moderate Buy” recommendation from brokers, which can underpin demand as investors digest guidance. Elevance Health, Inc. (NYSE:ELV) Given Average Recommendation of “Moderate Buy” by Brokerages
• Neutral Sentiment: Full Q4 materials and call transcript are available for investors wanting detail on membership, margins and Carelon performance; these provide context but don’t change the headline story. Elevance Q4 Slide Deck / Press Release
• Negative Sentiment: 2026 EPS guide misses Street: management set FY2026 EPS ~25.50, below the ~26.89 consensus, citing elevated medical costs—this is the primary driver of selling pressure and re-rating risk. Elevance forecasts 2026 profit below estimates on elevated medical costs (Reuters)
• Negative Sentiment: Margin and membership pressures: analysts flag medical membership declines, rising medical expenses and margin pressure that shape a weaker revenue/outlook profile for 2026. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts Shape 2026 Outlook
• Negative Sentiment: Medicare Advantage headwinds: the CMS proposed a very small 2027 MA rate increase (0.09%), a regulatory signal that intensified recent volatility and limited upside. Health Insurance Stock Could Rebound Off Historically Bullish Signal

Wall Street Analysts Forecast Growth

ELV has been the topic of several recent research reports. Weiss Ratings raised shares of Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. The Goldman Sachs Group started coverage on shares of Elevance Health in a research note on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price objective for the company. Wells Fargo & Company upped their price objective on shares of Elevance Health from $403.00 to $424.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Finally, Bank of America raised their target price on Elevance Health from $330.00 to $370.00 and gave the company a “neutral” rating in a report on Friday, October 10th. Twelve analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Elevance Health currently has an average rating of “Moderate Buy” and an average target price of $398.00.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.